Diaβeta® (glyburide) Tablets USP

Rx Only
1.25, 2.5 and 5 mg

DESCRIPTION
Diaβeta® (glyburide) is an oral blood-glucose-lowering drug of the sulfonylurea class. It is a white, crystalline compound, formulated as tablets of 1.25 mg, 2.5 mg, and 5 mg strengths for oral administration. Diaβeta tablets USP contain the active ingredient glyburide and the following inactive ingredients: dibasic calcium phosphate USP, magnesium stearate NF, microcrystalline cellulose NF, sodium alginic acid, talc USP. Diaβeta 1.25 mg tablets USP also contain D&C Yellow #10 Aluminum Lake and FD&C Red #40 Aluminum Lake. Diaβeta 2.5 mg tablets USP also contain D&C Yellow #10 Aluminum Lake and FD&C Blue #1. Chemically, Diaβeta is identified as 1-[p-(5-Chloro-anilidino)ethyl(phenyl) sulfonyl]-3-cyclohexylurea. The CAS Registry Number is 10238-21-8.

The structural formula is:

\[
\text{CONHCH}_2\text{CH}_3\text{SOONCONH}
\]

The molecular weight is 493.99. The aqueous solubility of Diaβeta increases with pH as a result of salt formation.

CLINICAL PHARMACOLOGY
Diaβeta appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreatic ß cells, an effect dependent upon functioning ß cells in the pancreatic islets. The mechanism by which Diaβeta lowers blood glucose during long-term administration has not been clearly established. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may play a part in the mechanism of action of oral sulfonylurea hypoglycemic drugs. In addition to its blood glucose lowering actions, Diaβeta produces a mild diuresis by enhancement of renal free water clearance. Clinical experience to date indicates an extremely low incidence of disulfiram-like reactions in patients while taking Diaβeta.

Pharmacokinetics
Single-dose studies with Diaβeta in normal subjects demonstrate significant absorption within one hour, peak drug levels at about four hours, and low but detectable levels at twenty-four hours. Mean serum levels of glyburide, as reflected by areas under the serum concentration-time curve, increase in proportion to corresponding increases in dose. Multiple-dose studies with Diaβeta in diabetic patients demonstrate drug level concentration-time curves similar to single-dose studies, indicating no build-up of drug in tissue deposits. The decrease of glyburide in the serum of normal healthy individuals is bimodal, the terminal half-life being about 10 hours. In single-dose studies in fasting normal subjects, the degree and duration of blood glucose lowering is proportional to the dose administered and to the area under the drug level concentration-time curve. The blood glucose lowering effect persists for 24 hours following single morning doses in non-fasting diabetic patients. Under conditions of repeated administration in diabetic patients, however, there is no reliable correlation between blood drug levels and fasting blood glucose levels. A one-year study of diabetic patients treated with Diaβeta showed no reliable correlation between administered dose and serum drug level. The major metabolite of Diaβeta is the 4-trans-hydroxy derivative. A second metabolite, the 3-cis-hydroxy derivative, also occurs. These metabolites contribute no significant hypoglycemic action since they are only weakly active (1/400th and 1/40th, respectively, as glyburide in rabbits). Diaβeta is excreted as metabolites in the bile and urine, approximately 50% by each route. This dual excretory pathway is qualitatively different from that of other sulfonylureas, which are excreted primarily in the urine.

Sulfonylurea drugs are extensively bound to serum proteins. Displacement from protein binding sites by other drugs may lead to enhanced hypoglycamic action. In vitro, the protein binding exhibited by Diaβeta is predominantly non-ionic, whereas that of other sulfonylureas (chlorpropamide, tolbutamide, tolazamide) is predominantly ionized. Acidic drugs such as phenytoin, warfarin, and salicylates displace the ion-binding sulfonylureas from serum proteins to a far greater extent than the non-ionic binding Diaβeta. It has not been shown that this difference in protein binding will result in fewer drug-drug interactions with Diaβeta in clinical use.

INDICATIONS AND USAGE
Diaβeta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

CONTRAINDICATIONS
Diaβeta is contraindicated in patients:
1. With known hypersensitivity to the drug or any of its excipients.
2. With type 1 diabetes mellitus or diabetic ketoacidosis, with or without coma.

These conditions should be treated with insulin.

Treated with bosantan.

WARNINGS
SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY
The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (Diabetes 19 (supp. 2): 747–830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2-1/2 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for this drug to show an increase in all-cause mortality. Despite the controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of Diaβeta and of alternative modes of therapy.

In the 5 mg once-daily class of oral sulfonylureas, only one class (Diaβeta) contains only one drug. In addition to the primary class comparison, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

Persons allergic to other sulfonylurea derivatives may develop an allergic reaction to glyburide as well.

PRECAUTIONS
General
MACROVASCULAR OUTCOMES
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Diaβeta or any other anti-diabetic drug.

Hypoglycemia
All sulfonylurea drugs are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemic episodes. Severe renal or hepatic insufficiency may cause elevated blood levels of Diaβeta and the latter may also diminish glucagonemic capacity, both of which increase the risk of serious, permanent, hypoglycemic reactions. Elderly, debilitated or malnourished patients, and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in patients with autonomic neuropathy, the elderly, and in people who are taking beta-adrenergic blocking drugs or other sympatholytic agents.

Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used. Loss of control of blood glucose: When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a loss of control may occur. At such times, it may be necessary to discontinue Diaβeta and administer insulin.

The effectiveness of any oral hypoglycemic drug, including Diaβeta, in lowering blood glucose to a desired level decreases in many patients over a period of time, which may be due to progression of the severity of the diabetes or to diminished responsiveness to the drug. This phenomenon is known as secondary failure, to distinguish it from primary failure in which the drug is ineffective in an individual patient when first given.

Hemolytic Anemia
Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because Diaβeta belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered. In postmarketing reports, hemolytic anemia has also been reported in patients who did not have known G6PD deficiency.

Information for Patients
Patients should be informed of the potential risks and advantages of Diaβeta and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose.

The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members.

Primary and secondary failure should also be explained.

Laboratory Tests
Periodic fasting blood glucose measurements should be performed to monitor therapeutic response. A glycosylated hemoglobin determination should also be performed periodically.

Drug Interactions
The hypoglycamic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, diisopropylamine, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, mononamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving Diaβeta, the patient should be observed closely for loss of control.

An increased incidence of elevated liver enzymes was observed in patients receiving glyburide concomitantly with bosantan. Therefore concomitant administration of Diaβeta and bosantan is contraindicated (see CONTRAINDICATIONS).

A potential interaction between oral miconazole and sulfonyluremic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical or vaginal preparations of miconazole is not known. A possible interaction between glyburide and fluoroquinolone antibiotics has been reported resulting in a potentiation of the hypoglycamic action of glyburide. The mechanism for this interaction is not known.

Possible interactions between glyburide and coumarin derivatives have been reported that may either potentiate or weaken the effects of coumarin derivatives. The mechanism of these interactions is not known.

Phenformin may worsen glucose control of glyburide because rifampin can significantly induce metabolic isozymes of glyburide such as CYP2C9 and 3A4.

Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calciumchannel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Diaβeta, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving Diaβeta, the patient should be observed closely for hypoglycemia.
Diazeta may increase cyclosporine plasma concentration and potentially lead to its increased toxicity. Monitoring and dosage adjustment of cyclosporine are therefore recommended when both drugs are coadministered.

Colestevam
Coadministration of colestevam and glyburide resulted in reductions in glyburide AUC and Cmax of 22% and 47%, respectively. When glyburide was administered 1 hour before colesvemol, the reductions in glyburide AUC and Cmax were 20% and 15%, respectively, and not significantly changed (7% and 4%, respectively) when administered 4 hours before colesvemol. Therefore, glyburide should be administered at least 4 hours prior to colesvemol.

Glyburide is mainly metabolized by CYP 2C9 and to a lesser extent by CYP 3A4. There is a potential for drug-drug interaction when glyburide is coadministered with inducers or inhibitors of CYP 2C9, which should be taken into account when considering concomitant therapy.

Carcinogenesis, Mutagenesis, and Impairment of Fertility
Diazeta is non-mutagenic when studied in the Salmonella microsome test (Ames test) and in the DNA damage/alkaline elution assay. Studies in rats at doses up to 300 mg/kg/day for 18 months showed no carcinogenic effects.

No drug-related effects were noted in any of the criteria evaluated in the two year oncogenicity study of glyburide in mice.

Pregnancy
Teratogenic Effects
Pregnancy Category C
Diazeta has been shown to affect the maturation of the long bones (humerus and femur) in rat pups when given in doses 6250 times the maximum recommended human dose. These effects, which were seen during the period of lactation and not during organogenesis, are a shortening of the bones with effects to various structures of the long bones, especially in humerus and femur.

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Diazeta should be used during pregnancy only if the potential benefit justifies the risk to the fetus. Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Nonteratogenic Effects
Prolonged severe hypoglycemia (4 to 10 days) has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Nursing Mothers
Although it is not known whether Diazeta is excreted in human milk, some sulfonylureas are known to be excreted in human milk. Because the potential for hypoglycemia in infants exposed to these drugs is of concern, a decision should be made whether to discontinue nursing or to discontinue administering the drug, taking into account the importance of the drug to the mother. If Diazeta is discontinued and diet alone is inadequate for controlling blood glucose, insulin therapy should be considered.

Pediatric Use
Safety and effectiveness in pediatric patients have not been established.

Geriatric Use
In elderly, debilitated, or malnourished patients, or in patients with renal or hepatic impairment, the effect of age on the pharmacokinetics of diazeta may be more pronounced. In elderly patients, the plasma half-life of diazeta is longer (15% to 20%) than in young adults. There is a need for caution in the administration of diazeta in elderly patients. When elderly patients are being treated with diazeta, their dose should be reduced, usually by about 50% to 75% of the initial dose. The initial and maintenance dosing should be conservative to avoid hypoglycemic reactions.

The initial and maintenance dosing should be conservative to avoid hypoglycemic reactions. The patient’s fasting blood glucose must be measured periodically to determine the minimum effective dose for the patient; to detect primary failure, to determine lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e., loss of adequate blood glucose lowering response after an initial period of effectiveness. Periodic glycosylated hemoglobin determinations should be performed.

Short-term administration of Diazeta may be sufficient during periods of transient loss of control in patients usually controlled well on diet.

1. Usual Starting Dose
The usual starting dose of Diazeta as initial therapy is 2.5 to 5 mg daily, administered with breakfast or the first main meal. Those patients who may be more sensitive to hypoglycemic drugs should be started at 2.5 mg daily. (See PRECAUTIONS Section for patients at increased risk). Failure to follow an appropriate dosage regimen may precipitate hypoglycemia. Patients who do not adhere to their prescribed dietary restrictions are more prone to exhibit unsatisfactory response to therapy.

Transfer of patients from other oral antidiabetic regimens to Diazeta should be done conservatively and the initial daily dose should be 2.5 to 5 mg. When transferring patients from oral hypoglycemic agents other than chlorpropamide, to Diazeta, no transition period is needed, because the risk of hypoglycemia is lower than with the other sulfonylureas. The dose of chlorpropamide should be reduced to one-third to one-half the previous dose. When transferring patients from chlorpropamide, particular care should be exercised during the first two weeks because the prolonged retention of chlorpropamide in the body and subsequent overlapping drug effects may provoke hypoglycemia.

Bioavailability studies have demonstrated that Glynase® Tablets USP 5 mg and Glynase® 2.5 tablets are not bioequivalent to Diazeta Tablets USP 5 mg. Therefore, these products are not substitutable and patients should be reinitiated.

Some Type II diabetic patients being treated with insulin may respond satisfactorily to Diazeta. If the insulin dose is less than 20 units daily, substitution of Diazeta 2.5 to 5 mg as a single daily dose may be tried. If the insulin dose is between 20 and 40 units daily, the patient may be placed directly on Diazeta 5 mg daily as a single dose. If the insulin dose is more than 40 units daily, a transition period is required for conversion to Diazeta. In these patients, insulin dosage is decreased by 50% and Diazeta 5 mg daily is started. Please refer to Usual Maintenance Dose for further explanation.

2. Usual Maintenance Dose
The usual maintenance dose is in the range of 1.25 to 20 mg daily, which may be given as a single dose or in divided doses (See Dosage Interval Section). Dosage increases should be made in increments of no more than 2.5 mg at weekly intervals based upon the patient’s blood glucose response.

No exact dosage relationship exists between Diazeta and the other oral hypoglycemic agents. Although patients may be transferred from the maximum dose of other sulfonylureas, the maximum starting dose of 5 mg of Diazeta should be observed. A maintenance dose of 5 mg Diazeta provides approximately the same degree of blood glucose control as 250 to 375 mg chlorpropamide, 250 to 375 mg tolazamide, 500 to 750 mg acetohexamide, or 1000 to 1500 mg tolbutamide. When transferring patients receiving more than 40 units of insulin daily, they may be started on a daily dose of Diazeta 5 mg concomitantly with a 50% reduction in insulin dose. Progressive withdrawal of insulin and increase of Diazeta in increments of 1.25 mg 2.5 mg 5 mg and 10 mg daily is then carried out, during this conversion period when both insulin and Diazeta are being used, hypoglycemia may rarely occur. During insulin withdrawal, patients should self-test their blood for glucose and their urine for acetone at least 3 times daily and report results to their physician. Self-testing of
urinary glucose is a less desirable alternative. The appearance of persistent acetonuria with glycosuria indicates that the patient is a Type I diabetic who requires insulin therapy.

3. Maximum Dose
Daily doses of more than 20 mg are not recommended.

4. Dosage Interval
Once-a-day therapy is usually satisfactory, based upon usual meal patterns and a 10 hour half-life of Diaβeta. Some patients, particularly those receiving more than 10 mg daily, may have a more satisfactory response with twice-a-day dosage.

In elderly patients, debilitated or malnourished patients, and patients with impaired renal or hepatic function, the initial and maintenance dosing should be conservative to avoid hypoglycemic reactions. (See PRECAUTIONS Section.)

Trademarks of their respective owners, not affiliated with sanofi-aventis.

HOW SUPPLIED
Diaβeta (glyburide) tablets USP are available in the following strengths and package sizes:

1.25 mg (peach, capsule-shaped, flat faced, beveled edge tablet debossed “Dia β” with a score line between the “Dia” and the “β” on one side and plain on the other side).
   Bottles of 50 (NDC 0039-0053-05)
2.5 mg (pink, capsule-shaped, flat faced, beveled edge tablet debossed “Dia β” with a score line between the “Dia” and “β” on one side and plain on the other side).
   Bottles of 100 (NDC 0039-0051-10)
5 mg (green, capsule-shaped, flat faced, beveled edge tablet debossed “Dia β” with a score line between the “Dia” and “β” on one side and plain on the other side).
   Bottles of 100 (NDC 0039-0052-10)

Bottles of 1000 (NDC 0039-0052-70)

Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [See USP Controlled Room Temperature].
Dispense in well-closed containers with safety closures.

Revised January 2017
sanofi-aventis U.S. LLC
Bridgewater, NJ 08807
A SANOFI COMPANY

©2017 sanofi-aventis U.S. LLC

GLY-FSPSL-SL-JAN17